Cargando…

Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in Mycobacterium tuberculosis in Southern India

Drug-resistant tuberculosis (TB), one of the leading causes of death worldwide, arises mainly from spontaneous mutations in the genome of Mycobacterium tuberculosis. There is an urgent need to understand the mechanisms by which the mutations confer resistance in order to identify new drug targets an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Munir, Asma, Kumar, Narender, Ramalingam, Suresh Babu, Tamilzhalagan, Sembulingam, Shanmugam, Siva Kumar, Palaniappan, Alangudi Natarajan, Nair, Dina, Priyadarshini, Padma, Natarajan, Mohan, Tripathy, Srikanth, Ranganathan, Uma Devi, Peacock, Sharon J., Parkhill, Julian, Blundell, Tom L., Malhotra, Sony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635374/ https://www.ncbi.nlm.nih.gov/pubmed/31311987 http://dx.doi.org/10.1038/s41598-019-46756-x

Ejemplares similares

Mycobacterium tuberculosis Lineages Associated with Mutations and Drug Resistance in Isolates from India
por: Shanmugam, Siva Kumar, et al.
Publicado: (2022)

Whole-Genome Sequencing to Identify Missed Rifampicin and Isoniazid Resistance Among Tuberculosis Isolates—Chennai, India, 2013–2016
por: Tamilzhalagan, Sembulingam, et al.
Publicado: (2021)

Differential Frequencies of Intermediate Monocyte Subsets Among Individuals Infected With Drug-Sensitive or Drug-Resistant Mycobacterium tuberculosis
por: Sampath, Pavithra, et al.
Publicado: (2022)

Genome Sequencing of Polydrug-, Multidrug-, and Extensively Drug-Resistant Mycobacterium tuberculosis Strains from South India
por: Shanmugam, Sivakumar, et al.
Publicado: (2019)

Downregulation of monocyte miRNAs: implications for immune dysfunction and disease severity in drug-resistant tuberculosis
por: Sampath, Pavithra, et al.
Publicado: (2023)

Fatal poisoning by isoniazid and rifampicin
por: Sridhar, A., et al.
Publicado: (2012)

Isoniazid- and rifampicin-induced thrombocytopenia
por: Yakar, Fatih, et al.
Publicado: (2013)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

Cytokine upsurge among drug-resistant tuberculosis endorse the signatures of hyper inflammation and disease severity
por: Sampath, Pavithra, et al.
Publicado: (2023)

Plasma chemokines CXCL10 and CXCL9 as potential diagnostic markers of drug-sensitive and drug-resistant tuberculosis
por: Sampath, Pavithra, et al.
Publicado: (2023)

Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin
por: Ramachandran, Geetha, et al.
Publicado: (2012)

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
por: Mukherjee, Aparna, et al.
Publicado: (2015)

Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro
por: Anderson, Ronald, et al.
Publicado: (2018)

Efficacy of T Regulatory Cells, Th17 Cells and the Associated Markers in Monitoring Tuberculosis Treatment Response
por: Agrawal, Sonali, et al.
Publicado: (2018)

A Case of Delusional Disorder With Abuse of Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol, the First-Line Anti-tuberculosis Therapy Drugs in India
por: Sathiyamoorthi, Sathiyanarayanan, et al.
Publicado: (2023)

Malnutrition: Modulator of Immune Responses in Tuberculosis
por: Chandrasekaran, Padmapriyadarsini, et al.
Publicado: (2017)

Protective Effects of Metallothionein on Isoniazid and Rifampicin-Induced Hepatotoxicity in Mice
por: Lian, Yong, et al.
Publicado: (2013)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study
por: Ramachandran, Geetha, et al.
Publicado: (2023)

Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018
por: Sayfutdinov, Zayniddin, et al.
Publicado: (2021)

Transcriptional Profiling and Deriving a Seven-Gene Signature That Discriminates Active and Latent Tuberculosis: An Integrative Bioinformatics Approach
por: Natarajan, Sudhakar, et al.
Publicado: (2022)

Rapid Detection of Rifampicin and Isoniazid Resistant Mycobacterium tuberculosis Using Genotype MTBDRplus Assay in Nepal
por: Sharma, Bijay Kumar, et al.
Publicado: (2014)

Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co–therapy
por: Li, Feng, et al.
Publicado: (2013)

Effectiveness of ellagic acid on isoniazid-rifampicin induced liver damage in rats
por: Ambrose, Samuel Stephen, et al.
Publicado: (2013)

Hepatoprotective Activity of Heptoplus on Isoniazid and Rifampicin Induced Liver Damage in Rats
por: Sankar, M., et al.
Publicado: (2015)

Naringenin protects against isoniazid- and rifampicin-induced apoptosis in hepatic injury
por: Wang, Chao, et al.
Publicado: (2016)

Simultaneous Spectrophotometric Determination of Rifampicin, Isoniazid and Pyrazinamide in a Single Step
por: Asadpour-Zeynali, Karim, et al.
Publicado: (2016)

Toxicoproteomic Profiling of hPXR Transgenic Mice Treated with Rifampicin and Isoniazid
por: Brewer, Christopher Trent, et al.
Publicado: (2020)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

Isoniazid, Pyrazinamide and Rifampicin Content Variation in Split Fixed-Dose Combination Tablets
por: Pouplin, Thomas, et al.
Publicado: (2014)

Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda
por: Sekaggya Wiltshire, Christine, et al.
Publicado: (2014)

Development and In Vitro Release of Isoniazid and Rifampicin-Loaded Bovine Serum Albumin Nanoparticles
por: Ge, Zhaohui, et al.
Publicado: (2018)

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
por: Kaboggoza, Julian P, et al.
Publicado: (2019)

Isoniazid and Rifampicin Produce Hepatic Fibrosis through an Oxidative Stress-Dependent Mechanism
por: Biswas, Ayan, et al.
Publicado: (2020)

Improved Stability of Rifampicin in the Presence of Gastric-Resistant Isoniazid Microspheres in Acidic Media
por: Mwila, Chiluba, et al.
Publicado: (2020)

Diagnostic performance of DNA microarray for detecting rifampicin and isoniazid resistance in Mycobacterium tuberculosis
por: Sun, Bingqi, et al.
Publicado: (2021)

Hepatoprotective activity of Ficus religiosa leaves against isoniazid+rifampicin and paracetamol induced hepatotoxicity
por: Parameswari, Sundaramoorthi Angala, et al.
Publicado: (2013)

Evaluation of Biochip System in Determining Isoniazid and Rifampicin Resistances of Mycobacterium Tuberculosis in Sputum Samples
por: Lu, Wei, et al.
Publicado: (2012)

Systems Pharmacology Approach Toward the Design of Inhaled Formulations of Rifampicin and Isoniazid for Treatment of Tuberculosis
por: Cilfone, NA, et al.
Publicado: (2015)

Rapid Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using Real-Time PCR
por: Sahebi, Leyla, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jh376escbm2rbef6be06llnj6m